Navigation Links
New Data Analyses on CONCERTA® Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD
Date:10/29/2010

percent or more of patients in either sub-analysis presented today were consistent with those previously reported for CONCERTA® and included decreased appetite, upper abdominal pain, headache, irritability and initial insomnia. Two patients discontinued due to adverse events. No serious adverse events or deaths were reported.

About the CONCERTA® Clinical Trials The two posters presented today are secondary analyses taken from a data set comprised of two randomized, double-blind, placebo-controlled, crossover analog simulated-classroom trials examining the effects of CONCERTA® compared with placebo. The trials included a general population of children with ADHD and a wide range of endpoints based on standardized ADHD measurements, as well as observational input from subjects' parents, teachers and healthcare providers.  

About ADHDAttention Deficit Hyperactivity Disorder (ADHD) is a common and treatable medical condition characterized by inattention, hyperactivity and impulsivity that is estimated to affect about 5 million children(4) and 8 million adults(5) in the United States. While the exact cause of the condition is still unknown, scientists have focused their research on chemical messengers, or neurotransmitters, in the brain.(6)   Studies suggest that 76 percent of ADHD is linked to family genetics,(6) so the condition may be more common among people who have a close relative with ADHD.(7)

About CONCERTA®CONCERTA® is a prescription medication approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents and adults ages 6 to 65, as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATIONTalk to your healthcare professional for a proper diagnosis and treatment of ADHD.  Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA®
'/>"/>

SOURCE McNeil Pediatrics(TM)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
2. Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
3. The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports
4. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
5. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
6. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
7. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
8. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
9. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... Inc. (NASDAQ: STXS ) announced today ... collaboration with Biosense Webster, Inc. related to Stereotaxis, ... broadest and most committed cooperative agreement around Odyssey ... Stereotaxis has granted Biosense Webster global, non-exclusive rights ...
... Calif., May 5, 2011 NeurogesX, Inc. (NASDAQ: ... novel pain management therapies, announced today that Anthony DiTonno, President ... 10th Annual JMP Securities Research Conference, to be held May ... Annual JMP Securities Research Conference Date : , Monday, ...
Cached Medicine Technology:Stereotaxis and Biosense Webster Announce New Strategic Collaboration 2Stereotaxis and Biosense Webster Announce New Strategic Collaboration 3Stereotaxis and Biosense Webster Announce New Strategic Collaboration 4NeurogesX to Present at 10th Annual JMP Securities Research Conference 2NeurogesX to Present at 10th Annual JMP Securities Research Conference 3
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Malaria Day at the Zoo to celebrate children helping children, a thank you ... congregations throughout West Ohio have contributed to the United Methodist initiative to end ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music ... Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best Drug ... underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best Drug ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a person ... with chemical dependency, may be able to find some hope in the latest ... center for addiction located in Western Michigan. Focusing on several different aspects of ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... LigoCyte Pharmaceuticals, Inc. announced today that its ... and related gastrointestinal illness collectively known as acute ... "the stomach flu" is one of the most ... and diarrhea afflicting 21 million Americans annually and ...
... -- Hispanic women have a 20 percent greater risk ... according to a new study. Biological differences in ... suggested. "This difference may be associated with a ... Baumgartner, an epidemiology professor at the School of Public ...
... By Mary Brophy Marcus HealthDay Reporter , WEDNESDAY, ... the outer layer of the brain and work its way ... upends long-held beliefs about the nervous system disease. The ... is diagnosed and treated, appear to solidify a theory that,s ...
... and the identification of sensitive biomarkers for early detection and/or ... New work published in the Dec. 7 issue of the ... the development of blood-based DNA markers for ovarian cancer. ... of Southern California in Los Angeles, found that a DNA ...
... Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... appears to boost survival in women with certain types ... These preliminary findings regarding the bone-building drug zoledronic acid ... their tumors. The studies are slated for presentation at ...
... By Steven Reinberg HealthDay Reporter , ... are screened for and diagnosed with low-risk prostate cancer, ... National Institutes of Health panel concluded that research on ... prostate cancer is discovered, many men opt for surgery ...
Cached Medicine News:Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 2Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 3Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 4Health News:Hispanic Women More Likely to Die of Breast Cancer 2Health News:MS May Take a Different Pathway Than Previously Thought 2Health News:MS May Take a Different Pathway Than Previously Thought 3Health News:Bone Drugs May Also Battle Breast Cancer, Researchers Say 2Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: